OncoMatch/Clinical Trials/NCT06143631
Prescription of Letrozole for Uterine Myoma
Is NCT06143631 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Letrozole 2.5mg for leiomyoma, uterine.
Treatment: Letrozole 2.5mg — The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: surgery or radiologic procedure for leiomyomata
Leiomyomata treated by surgery, radiologic procedure in the last 12 weeks; or plans to undergo any of the above in the next 24 weeks
Cannot have received: GnRH agonist or antagonist
Leiomyomata treated by GRNH agonist or antagonist in the last 12 weeks; or plans to use the above in the next 24 weeks
Cannot have received: aromatase inhibitor (letrozole)
Use of letrozole, other aromatase inhibitor, or selective estrogen receptor modulator (SERM) medications in the past 4 weeks, or existing plans to initiate one of these in the next 24 weeks
Cannot have received: selective estrogen receptor modulator
Use of letrozole, other aromatase inhibitor, or selective estrogen receptor modulator (SERM) medications in the past 4 weeks, or existing plans to initiate one of these in the next 24 weeks
Cannot have received: exogenous estrogen, progestin, or androgen therapy
Use of oral, vaginal, or topical exogenous estrogen, progestin, or androgen therapy in the past 4 weeks; or injectable forms of the above in the past 12 weeks; or plans to initiate any of the above in the next 24 weeks
Cannot have received: medications with potential unsafe interactions with letrozole (methadone, levomethadone, nintedanib, thalidomide)
Use of medications with potential unsafe interactions with letrozole in the past 4 weeks (methadone, levomethadone, nintedanib, thalidomide), or plans to initiate these in the next 24 weeks
Lab requirements
Blood counts
Screening serum hemoglobin <8 g/dL, or history of blood transfusion in the last 12 weeks (indicating severe anemia)
Screening serum hemoglobin <8 g/dL, or history of blood transfusion in the last 12 weeks (indicating severe anemia)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Los Angeles · Los Angeles, California
- University of California, San Francisco · San Francisco, California
- Mayo Clinic · Rochester, Minnesota
- University of Mississippi Medical Center · Jackson, Mississippi
- Duke University · Durham, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify